The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings

Annals of Internal Medicine

Volumn 156, Issue 4, 2012, Pages 263-270

  Rein, David B ^a   Smith, Bryce D ^b   Wittenborn, John S ^c   Lesesne, Sarah B ^d   Wagner, Laura D ^c   Roblin, Douglas W ^e   Patel, Nita ^b   Ward, John W ^b   Weinbaum, Cindy M ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c RTI INTERNATIONAL   (United States)

^d The University of North Carolina at Chapel Hill   (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

EID: 84863393363     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-4-201202210-00378     Document Type: Article

References (68)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14. [PMID: 16702586]
2. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005; 9:383-98, vi. [PMID: 16023972]
3. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331-8. [PMID: 12682882]
4. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14:107-15. [PMID: 17244250]
5. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of precirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43:66-72. [PMID: 20739252]
6. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology. 2008;47:1128-35. [PMID: 18318441]
7. Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med. 2000;108:366-73. [PMID: 10759092]
8. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-82. [PMID: 10706572]
9. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2004;8:iii-iv, 1-125. [PMID: 15461877]
10. Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, McQuillan G, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology. 2006;131:478-84. [PMID: 16890602]
11. Shepherd J, Brodin HF, Cave CB, Waugh NR, Price A, Gabbay J. Clinicaland cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care. 2005;21:47-54. [PMID: 15736514]
12. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47:1-39. [PMID: 9790221]
13. Kwiatkowski CF, Fortuin Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction. 2002;97:1289-94. [PMID: 12359033]
14. Culver DH, Alter MJ, Mullan RJ, Margolis HS. Evaluation of the effectiveness of targeted lookback for HCV infection in the United States-interim results. Transfusion. 2000;40:1176-81. [PMID: 11061852]
15. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2006;121:710-9. [PMID: 17278406]
16. Wasley A, Finelli L, Bell B, Alter M. The knowledge and behaviors of HCV-infected persons identified in a seroprevalence survey, USA, 2001-2002. J Clin Virol. 2006;36(Suppl 2):S198-9.
17. Antonucci G, Longo MA, Angeletti C, Vairo F, Oliva A, Comandini UV, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol. 2007;102:1383-91. [PMID: 17403072]
18. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237-44. [PMID: 12407599]
19. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-80. [PMID: 11106716]
20. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288-92. [PMID: 11848726]
21. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46:37-47. [PMID: 17567830]
22. Dudley T, O'Donnell K, Haydon G, Mutimer D. Disappointing results of combination therapy for HCV? [Letter]. Gut. 2006;55:1362-3. [PMID: 16905704]
23. Desmond CP, Roberts SK, Dudley F, Mitchell J, Day C, Nguyen S, et al. Sustained virological response rates and durability of the response to interferonbased therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat. 2006;13:311-5. [PMID: 16637861]
24. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24: 289-93. [PMID: 8690394]
25. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-32. [PMID: 9121257]
26. Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10:1-113, iii. [PMID: 16750059]
27. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-9. [PMID: 11029989]
28. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol. 2002; 156:761-73. [PMID: 12370165]
29. Planas R, Balleste ́ B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40:823-30. [PMID: 15094231]
30. Honeycutt AA, Harris JL, Khavjou O, Buffington J, Jones TS, Rein DB. The costs and impacts of testing for hepatitis C virus antibody in public STD clinics. Public Health Rep. 2007;122 Suppl 2:55-62. [PMID: 17542455]
31. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000; 343:1666-72. [PMID: 11106715]
32. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16. [PMID: 21696307]
33. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855-65. [PMID: 9382363]
34. Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health. 2004;81:25-37. [PMID: 15047781]
35. Ortner NJ, Cosway RG. 2005 US organ and tissue transplant cost estimates and discussion. Seattle, WA: Milliman Consultants and Actuaries; 2005.
36. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg. 2000;232:490-500. [PMID: 10998647]
37. Vlahov D, Wang C, Ompad D, Fuller CM, Caceres W, Ouellet L, et al; Collaborative Injection Drug User Study. Mortality risk among recent-onset injection drug users in five U.S. cities. Subst Use Misuse. 2008;43:413-28. [PMID: 18365941]
38. Rein DB, Lesesne SB, Smith BD, Weinbaum CM. Models of communitybased hepatitis B surface antigen screening programs in the U.S. and their estimated outcomes and costs. Public Health Rep. 2011;126:560-7. [PMID: 21800750]
39. Carey WD, Fried MW, Jeffers L, Kugelmas M, Layden TJ, Treisman G, et al. Hepatitis C management. In: The Cleveland Clinic, ed. The Cleveland Clinic Monograph Series. Cleveland: The Cleveland Clinic Foundation; 2007. Accessed at https://www.clevelandclinicmeded.com/online/monograph/HEPc/introduction.htmon30 October 2011.
40. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-71. [PMID: 15057920]
41. Gray L, Parkinson J, eds. The Essential RBRVS. Salt Lake City: St. Anthoney's Publishing; 2003.
42. American Medical Association. CPT 2006: Current Procedural Terminology (Standard Edition). Florence, KY: Thomson Delmar Learning; 2007.
43. Roblin D. Kaiser Permanente of Georgia Health System Reports. Atlanta: Kaiser Permanente; 2010.
44. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45:e17-24. [PMID: 20628308]
45. Englesbe MJ, Dimick J, Mathur A, Ads Y, Welling TH, Pelletier SJ, et al. Who pays for biliary complications following liver transplant? A business case for quality improvement. Am J Transplant. 2006;6:2978-82. [PMID: 17294525]
46. Haubolt RH. 2007 U.S. organ and tissue transplant cost estimates. Milwaukee, WI: Milliman; 2007. Accessed at http://publications.milliman.com/research /health-rr/pdfs/2007-US-Organ-Transplant-RR11-01-07.pdf on 30 October 2011.
47. Showstack J, Katz PP, Lake JR, Brown RS Jr, Dudley RA, Belle S, et al. Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA. 1999; 281:1381-6. [PMID: 10217053]
48. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290:228-37. [PMID: 12851278]
49. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health and Nutrition Examination Survey Data. 2001-2006. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2007.
50. Arias E. United States life tables, 2003. Natl Vital Stat Rep. 2006;54:1-40. [PMID: 16681183]
51. Vlahov D, Wang CL, Galai N, Bareta J, Mehta SH, Strathdee SA, et al. Mortality risk among new onset injection drug users. Addiction. 2004;99:946-54. [PMID: 15265091]
52. Thomson BJ, Kwong G, Ratib S, Sweeting M, Ryder SD, De Angelis D, et al; Trent HCV Study Group. Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. J Viral Hepat. 2008;15:271-8. [PMID: 18086181]
53. Mauss S, Rockstroh JK. HCV/HIV-coinfection-is there a state of the art after APRICOT and RIBAVIC? J Antimicrob Chemother. 2005;56:615-8. [PMID: 16115826]
54. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004;40:120-4. [PMID: 15239094]
55. Perrillo R, Rothstein KD, Rubin R, Alam I, Imperial J, Harb G, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat. 2004;11: 157-65. [PMID: 14996351]
56. Bureau of Labor Statistics. Household Data Annual Averages: 37. Median weekly earnings of full-time wage and salary workers by selected characteristics. Washington, DC: U.S. Bureau of Labor Statistics; 2010. Accessed at ftp://ftp.bls-.gov/pub/special.requests/lf/aat37.txt on 30 October 2011.
57. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36:778-92. [PMID: 9630120]
58. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98:630-8. [PMID: 12650799]
59. Siebert U, Wasem J, Rossol S, Sroczynski G, Aidelsburger P, Ravens- Sieberer U, et al. Antiviral treatment initiation costs in chronic hepatitis C [Letter]. Gut. 2005;54:172-3. [PMID: 15591531]
60. Sherman KE, Sherman SN, Chenier T, Tsevat J. Health values of patients with chronic hepatitis C infection. Arch Intern Med. 2004;164:2377-82. [PMID: 15557419]
61. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100:643-51. [PMID: 15743364]
62. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut. 2006;55:1332-8. [PMID: 15994216]
63. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31:52-61. [PMID: 16777543]
64. Centers for Disease Control and Prevention. Evaluation of elevated ALT as an anti-HCV screening criterion in comparison with birth cohort (1945-1965) criterion. Atlanta: Centers for Disease Control and Prevention; 2011.
65. Cassidy C. Health policy brief: health reform's changes in Medicare. Health Affairs. 20 May 2010. Accessed at www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id_17on 29October2011.
66. Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TES, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology. 2011;54:1547-58.
67. Beech BM, Myers L, Beech DJ, Kernick NS. Human immunodeficiency syndrome and hepatitis B and C infections among homeless adolescents. Semin Pediatr Infect Dis. 2003;14:12-9. [PMID: 12748917]
68. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138:187-90. [PMID: 12558357]